Q-omics provides the consensus-scored RPS15AP6 profile across patient tissues and cancer cell-line models. RPS15AP6 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RPS15AP6 is differentially expressed in 3, with the highest sampling consensus in HNSC. Additionally, RPS15AP6 RNA expression shows 8,588 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, HNSC, and GBM as cancer lineages where RPS15AP6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS15AP6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS15AP6 survival associations across molecular data types. RPS15AP6 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS15AP6 RNA expression–survival associations across cancer types. High RPS15AP6 expression shows unfavorable associations in KIRC, LIHC, ACC and COAD, but favorable associations in LUSC and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RPS15AP6 RNA expression.
This table summarizes RPS15AP6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for RPS15AP6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS15AP6 shows higher tumor expression in HNSC, STAD and READ. The HNSC box plot shows higher RPS15AP6 RNA expression in tumor versus normal tissue (log2 FC = +0.252, t-test p < 0.001).
This table shows molecular features associated with RPS15AP6 in patient tissues and cancer cell lines. In patient samples, RPS15AP6 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
